Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported a $13.2 million second-quarter loss as total revenue fell sharply from a year earlier despite record demand and higher U.S. …
Verrica Revenue Falls Despite Record YCANTH Demand Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will report second-quarter 2026 financial results on Aug. 6 and provide investors with a corporate update as the dermatology company continues …
Verrica Schedules Aug. 6 Earnings Call With Corporate Update Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has granted Medomie Pharma Ltd. exclusive rights to seek regulatory approval and commercialize its skin disease treatment YCANTH in Israel, expanding …
Verrica Expands YCANTH Rights to Israel in Licensing Deal Read More WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) has dosed the first U.S. patient in a second Phase 3 clinical trial evaluating YCANTH for common warts, expanding a late-stage development …
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported higher first-quarter revenue and accelerating demand for its YCANTH treatment as the company advances late-stage clinical trials that could significantly …
Verrica Expands YCANTH Sales as Wart Trials Advance Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it will present Phase 2 exploratory data on its investigational skin cancer treatment VP-315 at the 2026 Society for Investigative …
Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported financial results for the fourth quarter and full year ended December 31, 2025, citing growth in sales of its dermatology …
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will host a conference call and live webcast Wednesday to discuss its financial results for the fourth quarter …
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced it has appointed Chris Chapman as chief commercial officer to lead its U.S. commercial organization and support global expansion efforts.
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer Read More